MX2022012881A - Inhibidores de replicacion del virus de inmunodeficiencia humana. - Google Patents

Inhibidores de replicacion del virus de inmunodeficiencia humana.

Info

Publication number
MX2022012881A
MX2022012881A MX2022012881A MX2022012881A MX2022012881A MX 2022012881 A MX2022012881 A MX 2022012881A MX 2022012881 A MX2022012881 A MX 2022012881A MX 2022012881 A MX2022012881 A MX 2022012881A MX 2022012881 A MX2022012881 A MX 2022012881A
Authority
MX
Mexico
Prior art keywords
formula
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
Prior art date
Application number
MX2022012881A
Other languages
English (en)
Inventor
Kyle E Parcella
GILLIS Eric P
Gautam Dalwadi
Dawn D Parker
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2022012881A publication Critical patent/MX2022012881A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se expone una composición farmacéutica que comprende el compuesto de la Fórmula Ia, Fórmula Ib, Fórmula Ic o Fórmula Id, o una sal farmacéuticamente aceptable del mismo. (ver Fórmulas).
MX2022012881A 2020-04-15 2021-04-13 Inhibidores de replicacion del virus de inmunodeficiencia humana. MX2022012881A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010196P 2020-04-15 2020-04-15
US202063013576P 2020-04-22 2020-04-22
PCT/IB2021/053046 WO2021209900A1 (en) 2020-04-15 2021-04-13 Inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
MX2022012881A true MX2022012881A (es) 2022-11-08

Family

ID=75581554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012881A MX2022012881A (es) 2020-04-15 2021-04-13 Inhibidores de replicacion del virus de inmunodeficiencia humana.

Country Status (11)

Country Link
US (1) US20230149408A1 (es)
EP (1) EP4135702A1 (es)
JP (1) JP2023521460A (es)
KR (1) KR20230002629A (es)
CN (1) CN115397424A (es)
AU (1) AU2021256166B2 (es)
BR (1) BR112022020933A2 (es)
CL (1) CL2022002817A1 (es)
IL (1) IL297041A (es)
MX (1) MX2022012881A (es)
WO (1) WO2021209900A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240074850A (ko) * 2021-10-13 2024-05-28 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060085675A (ko) 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
JP5860197B1 (ja) 2013-01-09 2016-02-16 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症を処置するための治療用化合物
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
CA3021227C (en) 2016-08-19 2020-11-03 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
CA3090280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP2021530523A (ja) 2018-07-16 2021-11-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のためのカプシド阻害剤
US11919897B2 (en) * 2018-09-20 2024-03-05 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
EP4135702A1 (en) 2023-02-22
WO2021209900A1 (en) 2021-10-21
CN115397424A (zh) 2022-11-25
JP2023521460A (ja) 2023-05-24
BR112022020933A2 (pt) 2022-12-06
AU2021256166B2 (en) 2024-05-23
KR20230002629A (ko) 2023-01-05
US20230149408A1 (en) 2023-05-18
CL2022002817A1 (es) 2023-06-09
IL297041A (en) 2022-12-01
AU2021256166A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MY174224A (en) Hepatitis b virus surface antigen inhibitor
TW200518758A (en) HIV replication inhibiting purine derivatives
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
SI2932970T1 (en) Antiviral therapy
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2019006843A (es) Inhibidor de cdk4/6.
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
CR20230215A (es) Compuestos de pirimidina, composiciones y aplicaciones médicas de esta
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
SI1858861T1 (sl) 2-(4-cianofenil)-6-hidroksilaminopirimidini, ki inhibirajo HIV
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
EA202190398A1 (ru) Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4
EA202193007A1 (ru) Соединения пирролидина